Josh Brown Warns Against AI CapEx Focus, Highlights Top Healthcar
· investing
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks
Josh Brown, CEO of Ritholtz Wealth Management, has been making waves in the investment community by advocating for a shift away from the AI and data-center spending theme that has dominated the market. In a recent CNBC interview on Halftime Report, he explicitly stated that it’s time to take a break from this focus.
Brown’s sentiment resonates with many investors who have become caught up in the hype surrounding artificial intelligence and its applications. While excitement is palpable, warning signs are also evident. Brown’s decision to highlight two of his top healthcare stock picks – Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) – serves as a refreshing dose of reality.
The numbers don’t lie: both companies boast strong earnings performance, with revenue growth exceeding expectations. Investors should refocus on what truly matters: solid company fundamentals and a deep understanding of market dynamics. Incyte’s impressive earnings momentum and expanding drug pipeline make it an attractive investment opportunity.
Incyte has been a standout performer, with its stock price increasing 22% year-to-date. Brown’s bullish case centers around the company’s diversified portfolio, which includes nine or ten drugs at various stages of development. This diversification is crucial for long-term investing and has been overshadowed by the AI hype.
However, there are risks associated with relying too heavily on a single product. Incyte’s dependence on Jakafi’s success is still a concern, especially given the looming exclusivity loss in 2028. Competition from AbbVie’s Rinvoq could also put pressure on Opzelura’s European vitiligo business.
Brown’s decision to highlight Incyte and Biogen serves as a reminder that investing is not just about following trends or riding market excitement. It’s about understanding underlying fundamentals, identifying potential risks, and making informed decisions based on thorough analysis.
As investors, we would do well to heed Brown’s advice and take a break from the AI capex world. By doing so, we may discover more compelling investment opportunities grounded in solid company performance rather than speculative hype.
The question now is what’s next for investors: will they continue to chase AI-driven stocks or refocus on fundamentals? The answer lies not in the latest AI breakthroughs but in tried-and-true investing principles. As we move forward, it’s essential to remember that investing is a marathon, requiring patience, discipline, and adaptability.
Brown’s break from AI serves as a much-needed reality check for investors. It’s time to refocus on what truly matters: solid company fundamentals, diversified portfolios, and a deep understanding of market dynamics. By doing so, we may just find ourselves back on track, investing with a clear head and a steady hand.
Reader Views
- TLThe Ledger Desk · editorial
While Josh Brown's push for investors to take a break from AI CapEx is timely, his focus on Incyte and Biogen may be too narrow. He's right that solid company fundamentals are crucial, but healthcare stocks come with inherent risks. A more nuanced approach would consider the industry-wide challenges facing these companies, such as regulatory hurdles and patent expirations. Investors should carefully weigh the potential for growth against these risks before allocating funds to Incyte or Biogen.
- LVLin V. · long-term investor
While Josh Brown's call to shift focus from AI CapEx to solid company fundamentals is well-timed, investors should remain cautious of Incyte's over-reliance on Jakafi and potential exclusivity loss in 2028. Brown's emphasis on diversification is spot-on, but a deeper examination of the company's research pipeline reveals some promising assets, like retifanlimab, which could mitigate this risk to some extent. Prudent investors should keep a close eye on Incyte's pipeline developments and monitor its cash burn rate as it continues to invest in new areas.
- MFMorgan F. · financial advisor
While Josh Brown's advice to shift focus away from AI and data centers is timely, investors shouldn't dismiss the sector entirely just yet. Many of these companies have transformed their business models, investing heavily in AI-driven innovation that will drive future growth. The key is to identify those with a clear roadmap for monetizing this investment, such as Microsoft's Azure unit or Alphabet's Google Cloud Platform. By doing so, investors can capitalize on the secular shift towards cloud computing without getting caught up in hype surrounding individual stocks.